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Abstract
Background: Standard spirometry cannot identify the predominant mechanism underlying airflow obstruction in
COPD, namely emphysema or airway disease. We aimed at validating a previously developed methodology to
detect emphysema by mathematical analysis of the maximal expiratory flow-volume (MEFV) curve in standard
spirometry.
Methods: From the COPDGene population we selected those 5930 subjects with MEFV curve and inspiratory-
expiratory CT obtained on the same day. The MEFV curve descending limb was fit real-time using forced vital
capacity (FVC), peak expiratory flow, and forced expiratory flows at 25, 50 and 75% of FVC to derive an emphysema
severity index (ESI), expressed as a continuous positive numeric parameter ranging from 0 to 10. According to
inspiratory CT percent lung attenuation area below − 950 HU we defined three emphysema severity subgroups
(%LAA-950insp < 6, 6–14, ≥14). By co-registration of inspiratory-expiratory CT we quantified persistent (%pLDA) and
functional (%fLDA) low-density areas as CT metrics of emphysema and airway disease, respectively.
Results: ESI differentiated CT emphysema severity subgroups increasing in parallel with GOLD stages (p < .001), but
with high variability within each stage. ESI had significantly higher correlations (p < .001) with emphysema than
with airway disease CT metrics, explaining 67% of %pLDA variability. Conversely, standard spirometric variables
(FEV1, FEV1/FVC) had significantly lower correlations than ESI with emphysema CT metrics and did not differentiate
between emphysema and airways CT metrics.
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Conclusions: ESI adds to standard spirometry the power to discriminate whether emphysema is the predominant
mechanism of airway obstruction. ESI methodology has been validated in the large multiethnic population of
smokers of the COPDGene study and therefore it could be applied for clinical and research purposes in the general
population of smokers, using a readily available online website.
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Background
Expiratory airflow obstruction as detected by spirom-
etry is the hallmark of chronic obstructive pulmonary
disease (COPD). In each patient the relative contri-
bution of conductive airways narrowing and emphy-
sematous parenchymal destruction determines the
complexity and heterogeneity of the clinical presenta-
tion in COPD [1–4]. Emphysema is a major deter-
minant of lung function decline and all-cause
mortality in patients with COPD [5, 6]. Lung vol-
umes and diffusing capacity are traditionally used to
infer the presence and the severity of emphysema.
However, these measurements are not always avail-
able in clinical practice, not usually included among
the variables to enroll patients in large clinical and
pharmacologic trials, and considered not to be essen-
tial to patient management by the 2019 Report of
the Global Initiative for Chronic Obstructive Lung
Disease (https://goldcopd.org/).
Recently the application of computed tomography (CT)
to the study of COPD has provided information on the
pathological changes occurring in the disease [7, 8]. Bron-
chial wall thickening, gas trapping, and parenchymal de-
struction are qualitatively evaluated and quantitatively
assessed by dedicated software [9–12]. Identification of
the prevailing mechanism for expiratory airflow obstruc-
tion, i.e. airways disease vs. parenchymal destruction, can
be obtained by CT analyses, such as parametric response
maps from co-registration of inspiratory and expiratory
scans [13] and disease probability measure maps [14].
Quantitative evaluation of CT scans has been introduced
in large-scale COPD population studies [15, 16]. However,
the high prevalence of COPD in the general population
[17], the relative limited availability of CT and its intrinsic
use of ionizing radiation limit the use of CT imaging for
the diagnosis and treatment of COPD in clinical routine
as well as in large-scale clinical, epidemiologic, and
pharmacologic trials. Furthermore, CT metrics do offer a
quantitative evaluation of the extent of lung pathology but
no information on the mechanism of airflow limitation.
A model based on the mathematical fitting of the de-
scending limb of the maximal expiratory flow-volume
curve (MEFV) in standard spirometry can provide a
functional emphysema severity index (ESI) that strongly
correlates with the extent of emphysema on CT-based
radiomics, as demonstrated in a previous study con-
ducted in a small cohort of Caucasian patients with
COPD [18].
The aim of the present study was to validate by CT
metrics the ESI methodology for the assessment of em-
physema severity by standard spirometry in the large
multiethnic population of US subjects enrolled in the
COPDGene study, in order to demonstrate the
generalizability of the method for pharmacologic trials
and its utility in clinical care of former and current
smokers.
Methods
COPDGene is a multicenter study designed to identify
genetic factors, to characterize CT subtypes, and deter-
minants of progression. Study details have been previ-
ously published [16]. Institutional review boards
approved the study across the 21 US participating Clin-
ical Centers between January 2008 and June 2011 and all
participants provided written informed consent. COPD-
Gene included current and former smokers aged 45–80
years, either non-Hispanic whites or non-Hispanic Afri-
can Americans. The study included smoker controls
(GOLD 0), GOLD 1–4 and PRISm (Preserved Ratio Im-
paired Spirometry, i.e. FEV1/FVC ≥ 0.7 and post-
bronchodilator FEV1 < 80% of predicted) subjects for a
total of 10,371 subjects with at least 10 pack-years smok-
ing history [16]. All participants underwent spirometry
and inspiratory-expiratory CT.
Spirometry
All subjects underwent pre- and post- bronchodilator
spirometry using the NDD EasyOne Spirometer (Zurich,
Switzerland) according to the American Thoracic Soci-
ety criteria [19]. Pre-bronchodilator spirometry was
followed by administration of two puffs of albuterol
HFA using appropriate spacers such as Aerochamber®
(Monaghan Medical Corporation, Plattsburgh, NY).
Post-bronchodilator spirometry was performed 15–20
min post albuterol administration.
Quantitative CT analysis
Quantitative CT analysis was performed by VIDA (Cor-
alville, IA) [20] and Imbio LLC (Minneapolis, MN) soft-
ware programs [13]. VIDA was used to assess the
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percent of low attenuation area below -950HU at full in-
spiration (%LAA-950insp), below -856HU at end-tidal ex-
piration (%LAA-856exp), and the average wall thickness of
bronchi with 10 mm internal perimeter (AWTPi10).
Imbio was used to derive persistent low-density areas
(%pLDA) and functional low-density areas (%fLDA)
from co-registered inspiratory-expiratory CT scans
representing regions of emphysematous and non-
emphysematous gas-trapping, respectively.
Emphysema severity index (ESI)
The ESI software is designed to perform a fast fitting to
the descending limb of the MEFV curve suitable for
real-time analysis in clinical practice and for large data-
set in clinical and pharmacologic trials (freely available
for research at url: https://www.emphysema.app). The
ESI online app ultimately provides a continuous positive
numeric parameter ranging from 0 to 10 after receiving
discrete input parameters (PEF, FEF25, FEF50, FEF75,
FVC) derived from the MEFV curve obtained at spirom-
etry. The procedure is fully automated and the results
are calculated real -time. For theoretical background of
ESI see reference [18].
Data analysis
Association between ESI, FEV1, FEV1/FVC and CT met-
rics was assessed by Pearson’s r correlation and R2 deter-
mination coefficients. Robust Steiger’s Z-test was used to
assess statistical significance of the difference between cor-
relations [21]. Multiple regression analysis was performed
using ESI as dependent variable and %pLDA and %fLDA
as independent variables to further evaluate the associ-
ation profile between the three parameters. Subjects were
allocated in subgroups based on the %LAA-950insp cut-off
reported by the Fleischner Society for the presence and
the severity of emphysema: no emphysema (NE,
%LAA-950insp < 6), moderate emphysema (ME,
6 ≤%LAA-950insp < 14), and severe emphysema (SE,
%LAA-950insp ≥ 14) [7, 22]. Differences in ESI among
GOLD stages and CT emphysema severity subgroups
were assessed by one-way ANOVA and Welch’s t-test.
The distribution of CT subgroups (NE, ME, SE) within
the ESI value range from 0 to 10 was evaluated by contin-
gency table. Goodman and Kruskal’s gamma test was per-
formed to assess the strength of the association between
the different ranges of ESI and emphysema CT metrics.
All analyses were performed using SPSS (PCWIN
11.5.1, Chicago, IL, USA) and Orange software [23].
Two-sided alpha 0.05 was considered significant.
Results
From the 10,371 subjects enrolled in the COPDGene
study we excluded those with MEFV curves not satisfying
the standard quality criteria (n = 1397) or the automated
quality check by ESI program (n = 71), those with spirom-
etry and CT obtained in a different day (n = 1673), those
who had spirometry but no CT (n = 276), those who had
CT analyzed by VIDA software only (n = 945), and never
smokers (n = 79). ESI was calculated in 5930 smokers dis-
tributed across all GOLD stages (GOLD 0, n = 2446;
GOLD 1, n = 499; GOLD 2, n = 1169; GOLD 3, n = 662;
GOLD 4, n = 313) and PRISm (n = 641). Table 1 describes
the anthropometric, pulmonary function and CT metrics
data of the final population.
The correlation and the determination coefficients be-
tween functional parameters and CT metrics are re-
ported in Table 2. ESI had stronger correlations with
emphysema CT metrics (%LAA-950insp, %pLDA) than
standard functional parameters of airflow obstruction
(FEV1, FEV1/FVC). ESI had weaker correlations with air-
way disease (AWTPi10, %fLDA) than with emphysema
CT metrics (%LAA-950insp, %pLDA). Considering coeffi-
cients of determination (R2), ESI accounted for 35% of
Table 1 Anthropometric, pulmonary function and CT metrics
data of the 5930 subjects of the COPDGene population






Age (yr) 60.1 (8.9)
BMI (kg/m2) 28.8 (6.2)
Smoking history (pack/years) 44.2 (24.6)
FEV1 (%pred) 77.4 (25.0)
FVC (%pred) 87.9 (17.8)
FEV1/FVC 0.66 (0.16)
PEF (L/s) 6.4 (2.4)
FEF25% (L/s) 4.8 (2.6)
FEF50% (L/s) 2.5 (1.7)
FEF75% (L/s) 0.6 (0.5)








Data are expressed as mean (SD) or absolute numbers. AWTPi10 = Average
wall thickness of bronchi with an internal perimeter of 10 mm, BMI = Body
mass index, FEF = Forced expiratory flow, FEV1% = forced expiratory volume in
1 sec, %fLDA = percentage of functional low density area, FVC = Forced vital
capacity, GOLD = Global initiative for chronic Obstructive Lung Disease;
%LAA-950insp = percentage of lung attenuation area with values <− 950
Hounsfield Units at inspiratory CT scan, %LAA-856exp = percentage of lung
attenuation area with values <− 856 Hounsfield Units at expiratory CT scan,
PEF = Peak expiratory flow, %pLDA = percentage of persistent low density
area, %pred = percentage of predicted, PRISm = Preserved Ratio Impaired
Spirometry, i.e. FEV1/FVC ≥ 0.7 and post-bronchodilator FEV1 < 80% of
predicted; a parameters calculated by using VIDA software; b parameters
calculated by using Imbio software
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%fLDA variability while explaining roughly the double
(67%) of that of %pLDA. At variance with ESI, both
FEV1 and FEV1/FVC had similar R
2 values for emphy-
sema and airway disease CT metrics. Multiple regression
analysis demonstrated that the coefficient of determin-
ation R2 had only a small increase (from 0.67 to 0.71) of
predictive ability when adding %fLDA to the univariate
correlation of ESI with %pLDA. This indicates the speci-
ficity of ESI in detecting the emphysematous component
of whole airway obstruction.
Table 3 shows differences in ESI values across
GOLD stages and emphysema severity groups. All
GOLD groups differed significantly for ESI mean
values (Welch’s t- test p < 0.001), increasing in paral-
lel with GOLD stage with high variability within
each stage. ESI mean values of both PRISm and
GOLD 0 groups (0.9) were lower than those of
GOLD 1–4 groups. Likewise, all CT emphysema se-
verity groups differed significantly for ESI mean
values (Welch’s t-test p < 0.001).
Figure 1 shows the color-coded distribution of ESI
values (0–10) in a graph comparing functional gas
trapping (%fLDA, non-emphysematous gas trapping)
with total gas trapping (emphysematous and non-
emphysematous, as derived from the relative lung area
with CT attenuation below -856HU at expiration). Most
ESI values compatible with lower degrees of emphysema
were located around the identity line between the two
variables. Below 25–30% of total expiratory gas trapping
there were only few data points compatible with signifi-
cant emphysema, indicating that total gas trapping below
that level was apparently due only to functional gas trap-
ping. ESI values compatible with greater levels of em-
physema were mostly located above 30% of total gas
trapping and progressively dispersed above the identity
line with the increase in total gas trapping.
Figure 2 shows the distribution and the numerical de-
tails of the three CT subgroups (NE, ME, SE) among the
ranges of ESI values. The Goodman and Kruskal’s
gamma for the corresponding contingency table was
G = 0.82, p < 0.001. Ninety-two percent of subjects with
ESI ≤ 1 were classified at CT as NE, 7.3% as ME and
0.4% as SE group. On the other side, 94.1% of subjects
with ESI ≥ 9 values were classified at CT as SE, 5.3% as
ME and 0.5% as NE. Furthermore, with the progressive
increase of ESI values there was a gradual increase in the
percentage of subjects classified as SE and a gradual re-
duction in the percentage of subjects classified as NE.
For those classified at CT as ME we observed an in-
crease of the percentage of cases from ESI 0 to 2–3, then
a slight trend to reduction.
Discussion
We have demonstrated the utility of ESI in identifying
emphysema in a large and genetically diverse population
of current and former smokers. ESI when combined with
standard spirometric variables could help in discriminat-
ing the prevalent mechanism (i.e. emphysema or airway
disease) underlying airflow obstruction. The method
relies on each patient’s MEFV curve morphology as
Table 2 Pearson’s r correlations and determination coefficients
(R2) between continuous CT metrics of emphysema
(%LAA-950insp and %pLDA) or airway disease (% fLDA and
AWTPi10) and functional parameters
ESI FEV1 FEV1/FVC
r R2 p r R2 p r R2 p
%LAA-950insp
a 0.80 0.64 <.001 −0.60 0.36 <.001 −0.75 0.56 <.001
%pLDAb 0.82 0.67 <.001 −0.63 0.40 <.001 −0.74 0.55 <.001
%fLDAb 0.59 0.35 <.001 −0.58 0.34 <.001 −0.71 0.50 <.001
AWTPi10a 0.17 0.03 <.001 −0.34 0.12 <.001 −0.16 0.03 <.001
Legend: AWTPi10 = Average wall thickness of bronchi with an internal
perimeter of 10 mm, %fLDA = percentage of functional low density area,
%LAA-950insp = percentage of lung attenuation area with values <−950
Hounsfield Units at inspiratory CT scan, %pLDA = percentage of persistent low
density area, a parameters calculated by using Apollo (VIDA), b parameters
calculated by using Imbio
Table 3 Analysis of variance for ESI values among PRISm and GOLD stages and for subgroups with different emphysema severity
(%LAA-950insp) at CT
N ESI mean (SD) ANOVA /
Welch’s t-test
PRISm and GOLD stages PRISm 641 0.9 (0.4) p < .001
0 2646 0.9 (0.3)
1 499 1.4 (0.4)
2 1169 2.1 (1.1)
3 662 5.0 (2.1)
4 313 8.3 (2.0)
%LAA-950insp No Emphysema (< 6%) 4223 1.1 (0.8) p < .001
Moderate Emphysema (6–14%) 866 2.4 (2.0)
Severe Emphysema (≥14%) 841 5.9 (2.8)
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derived from absolute values of discrete spirometric vari-
ables, thus being independent of percent-predicted
values.
The forced expiratory maneuver is the basic lung
function test used to detect airflow obstruction [24].
In the late '70s, Saltzman [25] proposed that a “kink-
ing” of the descending limb of the MEFV curve might
represent a sign of airway collapse reflecting the pres-
ence of emphysema. In the following decades some
papers have considered the study of the MEFV curve
morphology as a possible method to distinguish nor-
mal aging from less paraphysiological airflow obstruc-
tion [26] or to predict emphysema [27–29] or chronic
bronchitis [30] by spirometry. All studies investigated
either the kinking in different portions of the MEFV
curve descending limb or its continuous flow-decay
(30) using mathematical linear models to approach
the curvilinear shape of the MEFV curve.
The shape of the MEFV curve has also been studied
to assess whether it could identify mild airflow ob-
struction in subjects with otherwise normal spirom-
etry [31, 32]. A recent study has shown that the area
under the MEFV curve could provide a superior esti-
mation of severe hyperinflation than conventional in-
dices like RV/TLC and IC/TLC in patients with
COPD [33]. However, these studies did not differenti-
ate the contribution of emphysema or small airway
disease to airflow obstruction. In a previous pilot
study, in a small population of patients with COPD,
it has been demonstrated that presence and severity
of emphysema as quantified by CT metrics and radio-
mics can be estimated by mathematical modeling of
Fig. 1 Distribution of the COPDGene population according to CT derived metrics: total expiratory gas trapping (y-axis, %LAA-856exp) and
functional gas trapping (x-axis, %fLDA). Data points are colored according to the corresponding ESI values calculated by spirometry (progressive
range 0–10). Total expiratory gas trapping entails the air trapped in the lungs at the end of a forced expiration due to both conductive airway
disease (functional gas trapping, %fLDA) and emphysematous parenchymal destruction, whose amount is represented by the ESI values
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airway function as derived from standard spirometry
[18]. Here we confirm in a larger population, includ-
ing smokers with normal lung function at standard
spirometry, that the analysis of MEFV curve descend-
ing limb can generate a functional index (ESI) that is
more strongly correlated than standard functional pa-
rameters with CT metrics indicative of emphysema
and to a considerably lesser extent with CT metrics
indicating airway disease. At variance with ESI the
correlation with emphysema or airway disease CT
metrics of standard functional parameters did not sig-
nificantly differ. These results support the ability of
ESI to specifically capture the emphysematous contri-
bution to airflow obstruction. The finding of similar
ESI values in PRISm and GOLD 0 groups further
support the specificity of ESI in detecting the pres-
ence of emphysema. Thus, ESI could complement the
assessment of airflow obstruction at spirometry to dif-
ferentiate patients with similar degrees of airflow ob-
struction but different degrees of emphysema severity.
Analysis of ESI values across CT subgroups of emphy-
sema severity showed either a significant progressive re-
duction or increase in ESI values in NE and SE
subgroups, respectively. Conversely, ESI values in ME
subgroup showed less consistency throughout the CT
subgroups. This could possibly be explained by the fact
that %LAA-950insp only represents extent of parenchymal
destruction as reflected by X-ray attenuation and not an
index of specific morphologic features in terms of em-
physema subtypes. ME subgroup may then include sub-
jects with mild emphysema, centrilobular or paraseptal.
Centrilobular and paraseptal emphysema less than 6%
extent on CT can be present also in NE patients (7).
This may cause some data dispersion in the correlation
between ESI and CT data. In fact, for the same level of
%LAA-950insp, centrilobular emphysema would affect the
MEFV curve morphology to a greater extent than para-
septal emphysema, which is located in the more periph-
eral regions of the lung. A relationship between the
qualitative CT features of the COPD subtypes observed
in the COPDGene population [34] and the correspond-
ing ESI values has not been performed yet. The study of
this relationship, which is out of the scope of this paper,
could be essential to confirm the speculations above.
The distribution of the large COPDGene population
according to total and functional gas trapping (Fig. 1) is
Fig. 2 Distribution of ESI values across the different emphysema subgroups as assessed by CT. White bars represent the percentages for NE (no
emphysema, %LAA-950insp < 6), light gray bars for ME (moderate emphysema, 6≤%LAA-950insp < 14), and dark gray bars for SE (severe emphysema,
%LAA-950insp≥ 14). Data in the table represent absolute numbers (percentages). The Goodman and Kruskal’s Gamma for the corresponding
contingency table is G = 0.82, p < 0.001
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in line with the previous observation that subjects with
an amount of total gas trapping around or below 30%
have negligible amounts of emphysema [12]. This sug-
gests that gas trapping in these subjects derives mostly
from the non-emphysematous component, in line with
recent data showing that terminal bronchioles are nar-
rowed and destroyed before the onset of emphysematous
changes [35]. If total gas trapping is around or above
30% the emphysema component adds to the non-
emphysematous one, resulting in progressive data dis-
persion above the identity line. We hypothesize that the
severity of emphysema is proportional to the distance
from the identity line that relates total gas trapping with
functional gas trapping. A longitudinal analysis of COPD
progression could ascertain whether the spectrum of the
disorder as observed in this study reflects different de-
grees of severity of the same disease or just different dis-
ease entities sharing airflow obstruction at spirometry.
Our study has several strengths. We analyzed a large
multiethnic population of smokers who underwent ex-
tensive phenotyping with spirometry and CT imaging.
Unlike previous studies [27, 28] we compared our results
with CT metrics deemed to reflect both emphysema and
airways disease. Our method is not a probabilistic pre-
dictive model trained on a specific learning set, but it de-
pends only on the specific shape of each MEFV curve.
An important step forward is the development of an ap-
plication for real-time analysis, making ESI suitable for
routine clinical use, for application on prospective wide-
scale clinical trials, and for application in post-hoc
analyses of previous randomized pharmacologic clinical
trials to evaluate the effects of emphysema severity on
the outcome.
Our study has also limitations. First, the method relies
on a well-performed MEFV curve. The automated qual-
ity check performed by ESI excluded only 71 patients in
whom spirometric data acquisition was closely con-
trolled. The number of patients excluded from the calcu-
lation of ESI could be higher in less controlled studies.
Second, we were unable to compare our score with the
severity of emphysema as assessed by absolute lung vol-
umes and diffusing capacity for carbon monoxide, as
these data as well as the measurement of slow vital cap-
acity (VC), were not available in the COPDGene study
at baseline. However, in a previous study ESI was
strongly correlated with absolute lung volumes and dif-
fusing capacity [18]. Third, we compared ESI with CT
metrics that reflect overall parenchymal destruction at
predefined attenuation thresholds as surrogate of em-
physema. However, the thresholds considered are those
generally used in studies comparing CT data with other
measurements. Fourth, expiratory CT scans were ac-
quired at end-tidal expiration and not at end-forced ex-
piration that correspond to the end of the expiratory
effort at spirometry. However, this difference in lung
volumes at expiration could have only reduced our valid-
ation performances by CT.
Conclusions
This study shows that the analysis of the MEFV curve
downslope can provide an index of emphysema presence
and severity (ESI), independent of percent-predicted
values, validated on CT scans and in the large multieth-
nic population of smokers of the COPDGene study.
Therefore, ESI can be applied for clinical and research
purposes in the general population of smokers to add to
standard spirometry the power to discriminate whether
emphysema or airways disease is the predominant mech-
anism of airway obstruction.
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